References
- Spencer FA, Lessard D, Emery C, et al. Venous thromboembolism in the outpatient setting. Arch Intern Med. 2007;167(14):1471–1475.
- Spyropoulos AC, Hussein M, Lin J, et al. Rates of venous thromboembolism occurrence in medical patients among the insured population. Thromb Haemost. 2009;102(5):951–957.
- Spyropoulos AC, Raskob GE. New paradigms in venous thromboprophylaxis of medically ill patients. Thromb Haemost. 2017;117(9):1662–1670.
- Spyropoulos AC, Anderson FA, FitzGerald G, et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011;140(3):706–714.
- Amin AN, Varker H, Princic N, et al. Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients. J Hosp Med. 2012;7(3):231–238.
- Amin AN, Lin J, Thompson S, et al. Real-world rates of in-hospital and postdischarge deep-vein thrombosis and pulmonary embolism in at-risk medical patients in the United States. Clin Appl Thromb Hemost. 2011;17(6):611–619.
- Mahan CE, Fisher MD, Mills RM, et al. Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population. Thromb Res. 2013;132(5):520–526.
- Cohen AT, Tapson VF, Bergmann J-F, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610):387–394.
- ACT Academy. Online library of quality service improvement and redesign tools: reducing length of stay; January 2018.
- Cohen AT, Spiro TE, Büller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368(6):513–523.
- Hull RD, Schellong SM, Tapson VF, et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010;153(1):8–18.
- Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365(23):2167–2177.
- Gibson CM, Nafee T, Yee MK, et al. Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients. Am Heart J. 2018;198:84–90.
- Chan NC, Bhagirath V, Eikelboom JW. Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. Vasc Health Risk Manag. 2015;11:343–351.
- Hutchaleelaha A, Ye C, Song Y, et al. Metabolism and disposition of betrixaban and its lack of interaction with major CYP enzymes. Blood. 2012;120(21):2266.
- Cohen AT, Harrington RA, Goldhaber SZ, et al. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med. 2016;375(6):534–544. .
- Cohen AT, Harrington RA, Goldhaber SZ, et al. Supplementary appendix: extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med. 2016;375(6).
- NICE. Clinical Guideline. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (Update); Published 2017. [cited 2017 November]. Available from: https://www.nice.org.uk/guidance/indevelopment/gid-cgwave0795/consultation/html-content-2
- Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis—principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health. 2014;17(1):5–14.
- Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98(4):756–764.
- Office for National Statistics. Population estimates for UK, England and Wales, Scotland and Northern Ireland: mid-2016 and mid-2004. [ cited 2017 Nov]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/populationestimatesforukenglandandwalesscotlandandnorthernireland
- Office for National Statisics. Population estimates for UK, England and Wales, Scotland and Northern Ireland: mid-2016; 2017 [cited 2017 Nov]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/bulletins/annualmidyearpopulationestimates/latest
- Cohen A, Hwang W, Harrington R, et al. Prevalence of major medical illnesses associated with venous thromboembolism risk in US hospitals. Int Soc Thrombosis Haemostasis. 2017. Congress presentation, Berlin.
- Office for National Statistics. How the population of England is projected to age. 2016 [cited 2017 Nov]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationprojections/compendium/subnationalpopulationprojectionssupplementaryanalysis/2014basedprojections/howthepopulationofenglandisprojectedtoage
- NICE Guideline NG89. Venous thromboembolism in over 16s. Appendices J - W. [cited 2018 Jul 24]. Available from: https://www.nice.org.uk/guidance/ng89/evidence/appendices-jw-pdf-4787002768. Published March 2018.
- Portola Data on File. Efficacy data from APEX; 2017.
- Portola Data on File. Network meta-analysis; 2017.
- Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41:3–14. .
- Prandoni P, Villalta S, Bagatella P, et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica. 1997;82(4):423–428.
- Pengo V, Lensing AWA, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350(22):2257–2264. .
- Mohan KM, Wolfe CDA, Rudd AG, et al. Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke. 2011;42(5):1489–1494. .
- Rouleau JL, Moye LA, Pfeffer MA, et al. A comparison of management patterns after acute myocardial infarction in Canada and the United States. N Engl J Med. 1993;328(11):779–784.
- Heit JA, Cohen AT, Andersen FA Jr. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood. 2005;106:910.
- Smolina K, Wright FL, Rayner M, et al. Incidence and 30-day case fatality for acute myocardial infarction in England in 2010: national-linked database study. Eur J Public Health. 2012;22(6):848–853.
- Office for National Statistics. National life tables: England and Wales 2014–2016; [ cited Oct 2017]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesenglandandwalesreferencetables
- Alter DA, Ko DT, Tu JV, et al. The average lifespan of patients discharged from hospital with heart failure. J Gen Intern Med. 2012;27(9):1171–1179.
- Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006;332(7537):325–329.
- British National Formulary; 2017 [cited Jul 2017]. Available from: https://bnf.nice.org.uk
- Curtis L, Burns A Unit costs of health and social care; 2016 [cited 2017 Nov]. Available from: http://www.pssru.ac.uk/project-pages/unit-costs/2016/index.php
- NICE. Single technology appraisal: Apixaban (Eliquis (R)) for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and the prevention of recurrent DVT and PE in adults. [cited 2017 November]. Available from: https://www.nice.org.uk/guidance/ta341/resources/deep-vein-thrombosis-pulmonary-embolism-treatment-secondary-prevention-apixaban-id726-committee-papers-2. Published 2014.
- NHS Reference Costs; 2015–2016 [cited Jul 2016]. Available from: https://www.gov.uk/government/publications/nhs-reference-costs-2015-to-2016
- NICE. Single technology appraisal of rivaroxaban (Xarelto®). [cited 2017 November]. Available from: https://www.nice.org.uk/guidance/ta256/documents/atrial-fibrillation-stroke-prevention-rivaroxaban-bayer4. Published 2011.
- NICE. Apixaban (Eliquis ®) for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation: single technology appraisal (STA); Published 2012. [cited 2017 November]. Available from: https://www.nice.org.uk/guidance/ta275/documents/stroke-and-systemic-embolism-prevention-nonvalvular-atrial-fibrillation-apixaban-bristolmyers-squibb-and-pfizer2
- Chi G, Yee MK, Amin AN, et al. Extended-duration betrixaban reduces the risk of rehospitalization associated with venous thromboembolism among acutely ill hospitalized medical patients. Circulation. 2018;137:91–94.
- Schilling B, Powers A, Faria C, et al. PCV32 BUDGET IMPACT ANALYSIS OF INCREASING LMWH/FXI UTILIZATION. Value Health. 2011;14(3):A38.
- Loo SY, Dell’Aniello S, Huiart L, et al. Trends in the prescription of novel oral anticoagulants in UK primary care. Br J Clin Pharmacol. 2017;83(9):2096–2106.
- Food and Drug Administration. BEVYXXATM Highlights of prescribing information; Published 2017. [cited 2018 March]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf
- Food and Drug Administration. FDA approved betrixaban (BEVYXXA, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients; [cited 2018 Mar 20]. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm564422.htm